title: Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study.
abstract: The prospective feasibility study was designed to determine whether treatment with antithrombin (AT) concentrates could be used for patients with severe preeclampsia to provide clinical efficacy without the full systemic antihypertensive drug. Twenty-nine severe preeclamptic patients (24 to 36 weeks of gestation, gestosis index [GI] >/= 6 points) were randomized to receive AT (1500 U/day) or not. AT was given intravenously once daily for 7 consecutive days. Twenty-four hours of continuous infusion of 5000 U/day of unfractionated heparin was given simultaneously in both groups. There were no statistical differences in the clinical profiles of the two groups. Maternal symptoms were evaluated from the difference of GI before and after treatment, and fetal findings were evaluated from the changes of the biophysical profile score. Improvement was significantly greater in the AT group for both the GI ( P = 0.046) and the biophysical profile score ( P = 0.022). The improvement of coagulation parameters was also evaluated. The improvement of plasmin-plasmin inhibitor complex (PPIC), D-dimer levels, and platelet counts was observed in the AT group compared with the non-AT group. The coagulation index as a composite coagulation test parameter showed a significantly improvement in the AT group. No adverse events related to AT were observed. Given that AT plus heparin was significantly better than treatment with heparin alone for improvement of both GI and biophysical profile of infant, it is suggested that therapy with AT alone might be effective enough for severe preeclampsia.
authors.affiliation: Shinshu University of Health Sciences, Matsumoto City, Nagano Prefecture, Japan. tkoba@gipac.shinshu-u.ac.jp
authors.forename: Takao
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Terao
authors.forename: Tsuyomu
authors.initials: T
authors.lastname: Ikenoue
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sameshima
authors.forename: Masao
authors.initials: M
authors.lastname: Nakabayashi
authors.forename: Yayoi
authors.initials: Y
authors.lastname: Kajiwara
authors.forename: Masahiro
authors.initials: M
authors.lastname: Maki
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use; D000991:Antithrombins / Q000008:administration & dosage / Q000627:therapeutic use*; D001794:Blood Pressure; D001835:Body Weight; D005240:Feasibility Studies; D005260:Female; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D010298:Parity; D018579:Patient Selection; D011225:Pre-Eclampsia / Q000188:drug therapy*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D006493:Heparin